000028 China National Accord Medicines Corporation
- 38.41
- -0.57-1.46%
China National Accord Medicines Corporation News
Express News | Tianfeng Securities: The pharmaceutical distribution sector is expected to usher in a valuation repair
Sinopharm unites (000028): Liangguang distribution leaders continue to unleash the operating potential of the national retail layout
Key investment points: The company's current position has the logic of double improvement in performance and valuation. 1) In terms of performance, the profitability of the retail business has great potential to improve. With the implementation of various gross profit improvement measures, the profitability of the retail business is expected to increase rapidly
Express News | Sinopharm agrees: the subsidiary Guokong Guangzhou Logistics Center won the bid for disease control warehousing and distribution business
Sinopharm is consistent (000028): Fee control effects are gradually showing optimism about improving profitability throughout the year
Core view On April 25, the company released the first quarter results report of 2024. In 24Q1, it achieved operating income of 19.090 billion yuan, an increase of 2.16% over the previous year, and achieved net profit of 389 million yuan to mother, an increase of 389 million yuan over the previous year
The pharmaceutical sector boosted and strengthened. Zhejiang Zhenyuan rose more than 5%, while Chinese Health, Heavy Pharmaceutical Holdings, Intel Group, Nanjing Pharmaceuticals, Sinopharm, and Kyushu Express followed suit.
The pharmaceutical sector boosted and strengthened. Zhejiang Zhenyuan rose more than 5%, while Chinese Health, Heavy Pharmaceutical Holdings, Intel Group, Nanjing Pharmaceuticals, Sinopharm, and Kyushu Express followed suit.
Sinopharm Unity (000028) Company In-depth Report: “Liangguang Distribution+National Retail” Dual Network Layout” Improving Quality and Efficiency “Accelerating Performance Growth”
Core investment logic: We believe that Sinopharm has the potential to “double hit Davis”. In terms of valuation, Sinopharm agrees that the current PE-TTM valuation is about 12 times (the average PE-TTM valuation in the past 5 years is about 13 times, China Special
Sinopharm is consistent (000028): Distribution business grows steadily and profitability continues to improve
Event: The company released its 2024 quarterly report, and the distribution sector grew steadily. 2024Q1 achieved operating income of 19.090 billion yuan, an increase of 2.16% year on year; net profit to mother was 389 million yuan, an increase of 7.
Sinopharm is consistent (000028): The performance is in line with expectations, and the distribution sector has achieved steady growth
The results for the first quarter of 2024 are in line with our expectations for the first quarter of 2024: the company achieved operating income of 19.090 billion yuan, an increase of 2.16% year on year; net profit to mother was 389 million yuan, an increase of 7 percent year on year.
Sinopharm is consistent (000028): Distribution is growing steadily, and retail growth is slowing down under a high base
Guide to this report: 2024Q1 distribution has maintained steady growth, and retail sales have declined due to the decline in high base growth, and the industry has contributed steady profits. With improvements in internal business quality and product restructuring, the company's net interest rate is expected to continue to rise. Key investment points: maintaining and increasing holdings
Sinopharm's consistent (000028) 2024Q1 performance review: steady distribution growth, retail growth decelerates under a high retail base
Guide to this report: 2024Q1 distribution has maintained steady growth, and retail sales have declined due to the decline in high base growth, and the industry has contributed steady profits. With improvements in internal business quality and product restructuring, the company's net interest rate is expected to continue to rise. Key investment points: maintaining and increasing holdings
Sinopharm is consistent (000028): stable growth in the 1Q distribution sector and improved profitability
1Q24 performance grew steadily, and profitability continued to improve the company's 1Q24 operating income/net profit attributable to mother/net profit of 190.90/3.89/370 million yuan, +2.16%/+7.33% year-on-year
Southwest Securities released a research report on April 16 stating that Sinopharm was given a consistent (000028.SZ) purchase rating. The main reasons for the rating include: 1) the fourth quarter results were under short-term pressure, and rates decline
Southwest Securities released a research report on April 16 stating that Sinopharm was given a consistent (000028.SZ) purchase rating. The main reasons for the rating include: 1) the fourth quarter results were under short-term pressure, and rates declined during the period; 2) the distribution business grew steadily and the profitability of the retail business increased; 3) National University Pharmacy increased its store expansion efforts and actively innovated online and offline multi-channel businesses. (Mainichi Keizai Shimbun)
Sinopharm agrees (000028): Steady expansion of stores in 2023, net interest rate increase in retail business
Incident: The company released its 2023 annual report, achieving full year operating income of 75.48 billion yuan (+2.8%), net profit of 1.6 billion yuan (+7.6%), and net profit of non-return to mother of 1.53 billion yuan (+7.6)
Sinopharm is consistent (000028): The distribution sector is growing steadily, and the retail business is improving quality and efficiency
Core view On April 7, the company released its 2023 annual results report. It achieved annual revenue of 75.477 billion yuan, an increase of 2.77% over the previous year, and achieved net profit of 1,599 billion yuan to mother, an increase of 7.57 billion yuan over the previous year
Sinopharm agrees (000028): 4Q distribution profit increased steadily and retail profit improved
4Q23 Revenue and net profit growth rate short-term pressure on the company's 2023 operating income/net profit attributable to mother/net profit excluding non-return to mother 754.77/15.99/$1,533 billion, +2.8%/+7.6% /+
Sinopharm Holdings (01099.HK): Sinopharm (000028.SZ)'s 2023 net profit of 1,599 billion yuan increased 7.57% year-on-year
Sinopharm Holdings (01099.HK) announced that its subsidiary Sinopharm Group Pharmaceutical Co., Ltd. (000028.SZ) achieved operating income of 75.477 billion yuan, up 2.77% year on year ended December 31, 2023; net profit attributable to shareholders of listed companies was 1,599 billion yuan, up 7.57% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1,533 billion yuan, up 7.58% year on year; basic earnings per share were 2.87 yuan/share.
Express News | Guokong Guangzhou signed a strategic cooperation agreement with Cochlear Co., Ltd.
Express News | Guokong Guangxi signed a platform strategic cooperation agreement with Tuoren Group
Sinopharm agrees (000028): revenue from the distribution sector will pick up in 2023, and the net profit margin of the retail sector will increase year-on-year
Revenue in 2023 is expected to increase 2.77% year on year, in line with our expectations. The company announced the 2023 performance forecast: operating income of 75.477 billion yuan, up 2.77% year on year, in line with our expectations; net profit to mother
Sinopharm agrees (000028): The base figure affects short-term performance and the growth rate is expected to pick up in 2024
Guide to this report: Distribution has maintained steady growth, retail revenue growth is slowing down due to the base effect, and the growth rate is expected to pick up in 2024; the company's net interest rate is expected to continue to improve as the results of the introduction and reform of high-margin products gradually become apparent. Key investment points: maintenance
Analysis
Price Target
No Data
